Download The roles of MED30 in pancreatic cancer cells Zaiqiu Cao1,2

The roles of MED30 in pancreatic cancer cells
Zaiqiu Cao1,2, Liangwen Liu1,2, Myoung-Eun Han1,2, Ji-Young Kim1,2,
Yun-Hak Kim1,2, Sae-Ock Oh1,2
1
Department of Anatomy, School of Medicine, Pusan National University,
2
Gene & Cell Therapy Research Center for vessel-associated diseases,
Yangsan 50612, Republic of Korea
Pancreatic cancer is the fourth leading cause of cancer-related death with highly
chemoresistant. Rapid progression and poor prognosis of pancreatic cancer shorten the
survival rate after the diagnosis. New diagnosis and therapeutic target need to be developed to
improve survival rate. MED30 was described as an essential member of mediator complex
which related with transcription. Frequent amplification of MED30 were observed in
pancreatic cancer patients of TCGA database. Moreover, the over-expression of MED30 was
also revealed in the immunohistochemistry of pancreatic cancer patient tissues. To reveal
function roles of MED30 during the progression of pancreatic cancer, we overexpressed or
knock-downed MED30 in using cDNA or siRNA. MED30 overexpression increased
proliferation, migration, and invasion of pancreatic cancer cells.
In contrast, MED30 knock-
down showed opposite effects. Furthermore MED30 overexpression promoted tumorigenicity
in SCID mice significantly. In conclusion, MED30 has pathophysiological roles in
proliferation, migration, and invasion of pancreatic cancer cells, Thus the MED30 could be a
potent diagnosis and therapeutic target in pancreatic cancer.